Treatment of recurrent glioblastoma: state-of-the-art and future perspectives.
Recurrent glioblastoma; glioblastoma; target therapy; immune-checkpoint inhibitors
Journal
Expert review of anticancer therapy
ISSN: 1744-8328
Titre abrégé: Expert Rev Anticancer Ther
Pays: England
ID NLM: 101123358
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
pubmed:
18
8
2020
medline:
15
4
2021
entrez:
18
8
2020
Statut:
ppublish
Résumé
Almost all patients affected by glioblastoma experience recurrence of the disease. Management of recurrent glioblastoma is a clinical challenge, and several elements should be taken into consideration when making treatment choice. Loco-regional treatments may be the best treatment approach in selected cases while systemic therapies or supportive care alone are necessary for other patients. Unfortunately, few drugs have shown clinical in this setting. This lack of effective treatments has made recurrent glioblastoma a disease orphan of an effective approach. Results of recent clinical trials offer interesting perspectives and may controvert this axiom.
Sections du résumé
BACKGROUND
Almost all patients affected by glioblastoma experience recurrence of the disease.
AREAS COVERED
Management of recurrent glioblastoma is a clinical challenge, and several elements should be taken into consideration when making treatment choice. Loco-regional treatments may be the best treatment approach in selected cases while systemic therapies or supportive care alone are necessary for other patients. Unfortunately, few drugs have shown clinical in this setting. This lack of effective treatments has made recurrent glioblastoma a disease orphan of an effective approach.
EXPERT OPINION
Results of recent clinical trials offer interesting perspectives and may controvert this axiom.
Identifiants
pubmed: 32799576
doi: 10.1080/14737140.2020.1807949
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM